Treatment of Liver Fibrosis in Adults with Nonalcoholic Steatohepatitis (NASH)

Last updated: September 5, 2023
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

3

Condition

Nonalcoholic Steatohepatitis (Nash)

Treatment

N/A

Clinical Study ID

TX228601
  • Ages 18-75
  • All Genders

Study Summary

Nash is liver inflammation and damage caused by a buildup of fat in the liver.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Male and female subjects aged between 18-75 years.
  • Histological evidence of NASH.
  • Histological evidence of Stage 2 or 3 liver fibrosis.
  • Historical biopsy was obtained no more than 180 days prior to the first day of screening.
  • Females of childbearing potential and males participating in the study must agree to use at least 2 approved methods of contraception throughout the duration of the study and for 30 days after stopping study drug.
  • Females who are postmenopausal must have documentation of cessation of menses for ≥12 months without an alternative medical cause.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Connect with a study center

  • Direct Helpers Research Center

    Hialeah, Florida 33012
    United States

    Active - Recruiting

  • Direct Helpers Research Center

    Hialeah, Florida 33012
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.